Clinical Trials Sponsored by Jarmo Oksi

Total 98 results

Jarmo Oksi

Completed

COVID-19: Salvage TOcilizumab as a Rescue Measure (COVIDSTORM)

Covid19

Finland
Tambi Jarmi

Withdrawn

Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI)

Ischemia Reperfusion Injury

United States
Orsi Academy

Enrolling by invitation

PBP vs Traditional Training: the T-REC Trial (T-REC)

Educational Problems

Belgium
Orsi Academy

Completed

Orsi Surgical Skills E-learning Trial (OSSET)

Surgery | E-learning

Belgium
Petra Larmo
Cliniscan Ltd

Terminated

Effects of a Berry Oil Cream on Atopic Eczema and Skin

Atopic Dermatitis Eczema

Finland
Eli Lilly and Company
ARMO BioSciences

Active, not recruiting

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (IVY)

Melanoma | Renal Cell Carcinoma | Breast Cancer | Ovarian Cancer | Prostate Cancer | Non-small Cell Lung Carcinoma | Solid Tumors | Colorectal Carcinoma | Pancreatic Carcinoma

United States
Eli Lilly and Company
ARMO BioSciences

Terminated

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (Cypress 1)

Non Small Cell Lung Cancer

United States
Eli Lilly and Company
ARMO BioSciences

Completed

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (Sequoia)

Pancreatic Cancer

United States, Belgium, Spain, Poland, Korea, Republic of, Taiwan, Germany, Italy, France, United Kingdom, Austria, Australia, Canada
Eli Lilly and Company
ARMO BioSciences

Completed

A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) (Willow 2)

Healthy Adult Subjects

United States
OSI Pharmaceuticals

Completed

A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer

Locally Advanced or Metastatic Adenoca of the Biliary Tract

United States, Belgium, Germany, Poland, Romania, Switzerland
OSI Pharmaceuticals

Completed

Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors

Advanced Solid Tumors

United States
OSI Pharmaceuticals

Completed

A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy

Locally Recurrent or Metastatic Cancer of the Head and Neck | Must Have Failed First-Line Therapy

United States
OSI Pharmaceuticals

Completed

Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer

Gastric Adenocarcinoma | Gastroesophageal Adenocarcinoma

United States, United Kingdom, Belgium
Eli Lilly and Company
ARMO BioSciences

Terminated

Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (Cypress 2)

Non Small Cell Lung Cancer

United States
Eli Lilly and Company
ARMO BioSciences

No longer available

An Expanded Access Program for AM0010 (Pegilodecakin)

Melanoma | Renal Cell Carcinoma | Breast Cancer | Ovarian Cancer | Prostate Cancer | Non-small Cell Lung Carcinoma | Solid Tumors | Colorectal Carcinoma | Pancreatic Carcinoma
Eli Lilly and Company
ARMO BioSciences

Completed

A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants (Willow 3)

Healthy

United States
Eli Lilly and Company
ARMO BioSciences

Completed

A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) (Willow 1)

Healthy Adult Subjects

United States
Stefano Puliatti

Completed

PBP Versus Halsted's Model: the PROVESA Trial (PROVESA)

Educational Problems

Belgium
Mayo Clinic
OSI Pharmaceuticals

Completed

Exisulind Versus Placebo After Surgical Removal of the Prostate

Prostatic Neoplasms

United States
Emory University
OSI Pharmaceuticals

Terminated

A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer

Liver Cancer

United States
Indiana University
OSI Pharmaceuticals

Completed

Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia

Leukemia, Myelomonocytic, Acute

United States
Northwestern University
OSI Pharmaceuticals

Withdrawn

Erlotinib for Treatment of Psoriasis

Psoriasis

United States
Emory University
OSI Pharmaceuticals

Withdrawn

A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies

Neoplasms | Cancer | Tumors

United States
University of Arkansas
OSI Pharmaceuticals

Terminated

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

Metastatic Breast Cancer

United States
OSI Pharmaceuticals

Terminated

Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma (PETEY)

Recurrent or Refractory Pediatric Ependymoma

United States, Canada, United Kingdom
OSI Pharmaceuticals

Terminated

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Ependymoma

United States, Canada, United Kingdom
OSI Pharmaceuticals

Completed

A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function

Advanced Solid Tumors

United States, United Kingdom
NYU Langone Health
OSI Pharmaceuticals

Terminated

Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

Ovarian Cancer

United States
University of Oklahoma
OSI Pharmaceuticals

Terminated

Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera (OSI-TAR-766)

Polycythemia Vera

United States
OSI Pharmaceuticals

Completed

A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors (RADIANT)

Non-small Cell Lung Cancer

United States, Hungary, Spain, Taiwan, Korea, Republic of, Italy, United Kingdom, Canada, Australia, Belgium, Germany, Austria, Poland, Romania, Argentina, France, Czech Republic, Greece, Russian Federation
OSI Pharmaceuticals

Completed

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

Non-Small Cell Lung Cancer

United States
OSI Pharmaceuticals

Completed

Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

Carcinoma, Non-Small-Cell Lung

United States, United Kingdom
OSI Pharmaceuticals

Completed

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

NSCLC

United Kingdom, United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

SCLC | Carcinoma, Small Cell

United Kingdom, United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

Ovarian Neoplasms

United Kingdom, United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Study of CP-461 in Patients With Advanced Renal Cell Cancer

Renal Cell Carcinoma

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase 1 Study of OSI-930 in Cancer Patients

Advanced Solid Tumors

United States, United Kingdom
University of Pittsburgh
OSI Pharmaceuticals

Completed

Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

United States
OSI Pharmaceuticals

Completed

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

United States
University of Washington
OSI Pharmaceuticals

Completed

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

Prostate Cancer

United States
OSI Pharmaceuticals

Completed

Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer | Failed Prior Chemotherapy

United States
University of Pittsburgh
OSI Pharmaceuticals

Withdrawn

Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)

Skin Rash

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients

Non-Small Cell Lung Cancer

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

NSCLC

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Advanced Solid Tumors

United States, United Kingdom
M.D. Anderson Cancer Center
OSI Pharmaceuticals

Terminated

Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin

Skin Cancer

United States
NYU Langone Health
Bayer; OSI Pharmaceuticals

Completed

Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer

Pancreatic Cancer

United States
M.D. Anderson Cancer Center
OSI Pharmaceuticals

Withdrawn

Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Cancer
Duke University
Genentech, Inc.; OSI Pharmaceuticals

Completed

Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme

Glioblastoma | Gliosarcoma

United States

Clinical Trials Sponsored by Jarmo Oksi

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations